相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019
Deepa Jahagirdar et al.
Lancet HIV (2021)
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa
Kim Steegen et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2021)
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study
Casey L. Smiley et al.
LANCET HIV (2021)
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
Adriani Nikolakopoulou et al.
PLOS MEDICINE (2020)
Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016
Julia L. Marcus et al.
JAMA NETWORK OPEN (2020)
Doravirine and Its Potential in the Treatment of HIV: An Evidence-Based Review of the Emerging Data
Alexander E. Rock et al.
HIV AIDS-RESEARCH AND PALLIATIVE CARE (2020)
Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries
Brian Godman et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2020)
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
Chloe Orkin et al.
CLINICAL INFECTIOUS DISEASES (2019)
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1
A. Ayouba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naive patients with CD4<200 cells/uL (the PRADAR study)
Cristina Mussini et al.
PLOS ONE (2019)
Network meta-analysis: application and practice using R software
Sung Ryul Shim et al.
EPIDEMIOLOGY AND HEALTH (2019)
Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis
S. Gallien et al.
HIV MEDICINE (2018)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial
Roland Landman et al.
ANTIVIRAL THERAPY (2014)
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
Rebekah L. Puls et al.
LANCET (2014)
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial
Takeshi Nishijima et al.
INTERNAL MEDICINE (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks
Judith A. Aberg et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
Calvin J. Cohen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
Vicente Soriano et al.
ANTIVIRAL THERAPY (2011)
Open-Label Randomized Multicenter Selection Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine
Miwako Honda et al.
INTERNAL MEDICINE (2011)
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients
E. DeJesus et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naive patients: A 48-week, multicentre, randomized study (Lake Study)
P. Echeverria et al.
ANTIVIRAL RESEARCH (2010)
Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study
Rebekah L. Puls et al.
CLINICAL INFECTIOUS DISEASES (2010)
Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir in HIV plus Treatment-Naive Subjects With CD4(+)< 200 cell/mm(3) in Mexico
Juan Sierra-Madero et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study
Frank A. Post et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
Kimberly Y. Smith et al.
AIDS (2009)
A Randomized, Open-Label Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor-Sparing Regimen in Antiretroviral-Naive HIV-Infected Patients
Marianne Harris et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Roberto Ortiz et al.
AIDS (2008)
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Jean-Michel Molina et al.
LANCET (2008)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
E DeJesus et al.
CLINICAL INFECTIOUS DISEASES (2004)
分享论文
